Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

MRNA vaccine technology stories

Nov 6, 2026

GSK and Moderna settle patent dispute over COVID and RSV vaccines

GSK has settled lawsuits accusing Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, resolving a major intellectual property dispute between the two drugmakers.

Nov 6, 2026·2 sources
00

Moderna posts first quarterly profit in two years, raises revenue forecast

Moderna swung to profit in Q3 2026, driven by strong international COVID-19 vaccine sales and partnership payments, and raised its full-year revenue guidance. The company also highlighted momentum for its mRNA-based cancer vaccine pipeline.

Nov 6, 2026·5 sources
00
Oct 22, 2026

Moderna and Merck melanoma vaccine cuts death or recurrence risk by 42% in phase 3 trial

The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.

Oct 22, 2026·5 sources
00
Oct 14, 2026

Merck CEO says cancer vaccine with Moderna will become faster to manufacture

Merck CEO Rob Davis said he expects the personalized cancer vaccine being developed with Moderna to have a shortened production timeline from its current six-week manufacturing period. The announcement comes after the companies reported promising late-stage trial results in August for the mRNA vaccine combined with immunotherapy for melanoma.

Oct 14, 2026·4 sources
00
Sep 19, 2026

mRNA cancer vaccines expand beyond melanoma to lung and pancreatic cancer trials

Following the breakthrough success of an mRNA melanoma vaccine, clinical trials are now underway testing similar vaccine technology for lung cancer, pancreatic cancer, and other diseases.

Sep 19, 2026·1 source
00
Aug 28, 2026

BioNTech halts colorectal cancer vaccine trial after safety review finds treatment unlikely to extend survival

BioNTech ended a mid-stage study of its experimental mRNA cancer vaccine after an independent committee determined the treatment was unlikely to help colorectal cancer patients live longer.

Aug 28, 2026·2 sources
00
Aug 19, 2026

Moderna and Merck's mRNA cancer vaccine reduces melanoma recurrence in late-stage trial

Moderna and Merck announced positive results from a Phase 3 trial showing their personalized mRNA cancer vaccine, combined with Keytruda, significantly reduced melanoma recurrence and spread. The companies aim to bring the therapy to market in 2027.

Aug 19, 2026·6 sources
00
Aug 6, 2026

Malaria Research Advances on Multiple Fronts as Drug Resistance Grows and New Vaccine Technologies Emerge

Scientists report progress in malaria vaccine development with new antibody-targeting approaches, while separate research reveals increasingly sophisticated drug resistance in malaria parasites. Meanwhile, FDA approval of Moderna's mRNA flu vaccine strengthens the case for applying mRNA technology to malaria and other diseases.

Aug 6, 2026·3 sources
00

Malaria Research Advances on Multiple Fronts as Drug Resistance Grows and New Vaccine Technologies Emerge

Scientists report progress in malaria vaccine development with new antibody-targeting approaches, while separate research reveals increasingly sophisticated drug resistance in malaria parasites. Meanwhile, FDA approval of Moderna's mRNA flu vaccine strengthens the case for applying mRNA technology to malaria and other diseases.

Aug 6, 2026·3 sources
00

FDA approves Moderna's mFlusiva, first mRNA-based flu vaccine in the United States

The Food and Drug Administration approved Moderna's mFlusiva on Wednesday, marking the first mRNA-based influenza vaccine authorized in the U.S. The vaccine is approved for adults aged 50 and older, representing a significant expansion of mRNA technology beyond COVID-19 vaccines.

Aug 6, 2026·6 sources
00
Aug 5, 2026

UK Approves First Trial of Moderna-Oxford mRNA Vaccine to Prevent Lynch Syndrome Cancers

UK regulators have authorized the INTERCEPT-Lynch Phase 1/2 trial of mRNA-4194, a preventive cancer vaccine developed by Moderna and the University of Oxford targeting people with Lynch syndrome, an inherited condition affecting 1 in 300 people with up to 80% lifetime cancer risk. The trial will begin dosing in summer 2026.

Aug 5, 2026·9 sources
00
Jun 1, 2026

Moderna's personalized mRNA melanoma vaccine cuts cancer recurrence risk by half in five-year trial results

New clinical trial results presented at the American Society of Clinical Oncology show that Moderna's experimental personalized mRNA vaccine, combined with immunotherapy, significantly reduced the risk of deadly melanoma returning after five years. The vaccine is custom-made for each patient based on their specific tumor.

Jun 1, 2026·4 sources
00
Apr 19, 2026

mRNA Cancer Vaccines Show Effectiveness Even Without Key Immune Cells in New Research

Scientists discovered that mRNA cancer vaccines can still destroy tumors even when a key immune cell type is missing, revealing unexpected mechanisms of action. The research advances understanding of how Nobel Prize-winning mRNA technology can be adapted from COVID-19 vaccines to fight cancer.

Apr 19, 2026·1 source
00

Top claims

  • ▪GSK and Moderna settled all pending patent infringement lawsuits regarding Moderna's COVID-19 vaccines Spikevax and mNEXSPIKE and RSV vaccine mResvia
  • ▪Moderna reported third-quarter 2026 total revenue of $1.313 billion, representing a 29% increase from $1.016 billion in the third quarter of 2025
  • ▪The U.S. Food and Drug Administration granted accelerated approval for Moderna's mFLUSIVA for adults aged 65 and older, contingent on a confirmatory efficacy study

People involved

Robert F. Kennedy Jr.

Subtopics

Clinical trials8Cancer immunotherapy7Drug Approval and Clinical Trials7Drug Policy, Pricing & Approval7Vaccines and Immunization Policy7Cancer & Oncology5Personalized medicine5Vaccine development and innovation5FDA drug approval4Vaccine development4Cancer treatment breakthroughs3Clinical evaluation3Clinical Trial Design & Evaluation3COVID-19 vaccines3Pharmaceutical Industry3Cancer treatment2Cancer Types2Oncology2Cancer1Clinical Genomics & Genetics1Corporate earnings1Drug development1Genetic disorders1Immunotherapy1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Payments

118 stories

Russia-Ukraine war

136 stories